The Decentralised procedure used for the registration of ROVIs biosimilar of enoxaparin has been completed with positive outcome.


No votes yet
 
Related
The operating revenue of Laboratorios Farmacéuticos ROVI increased by 8% to 82.2 million euros in the first quarter of 2019, mainly driven...
5 min
08/05/2019
Laboratorios Farmacéuticos Rovi, S.A. (www.rovi.es) today announced topline results from the pivotal study PRISMA-3, a multicenter,...
4 min
19/03/2019
The operating revenue of Laboratorios Farmacéuticos ROVI increased by 10% to 303.2 million euros in 2018, driven mainly by the strength of...
5 min
26/02/2019